The gold standard of clinical trial end points is survival. Since prostate cancer tends to move relatively slowly it can take many years for a clinical trial to be completed. We need better surrogate endpoints for survival so that trials can be completed more quickly allowing new drugs to flow to us.
Stand Up To Cancer announced an initiative that will both help scientists understand the emerging coronavirus pandemic and ensure the needs of cancer patients and survivors are being included as the research goes forward.
